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Abstract
Background: Proteinase-activated-receptor-2 (PAR2) is a seven transmembrane receptor that can activate two
separate signaling arms: one through Gaq and Ca
2+ mobilization, and a second through recruitment of b-arrestin
scaffolds. In some cases downstream targets of the Gaq/Ca
2+ signaling arm are directly inhibited by b-arrestins,
while in other cases the two pathways are synergistic; thus b-arrestins act as molecular switches capable of
modifying the signal generated by the receptor.
Results: Here we demonstrate that PAR2 can activate adenosine monophosphate-activated protein kinase (AMPK),
a key regulator of cellular energy balance, through Ca
2+-dependent Kinase Kinase b (CAMKKb), while inhibiting
AMPK through interaction with b-arrestins. The ultimate outcome of PAR2 activation depended on the cell type
studied; in cultured fibroblasts with low endogenous b-arrestins, PAR2 activated AMPK; however, in primary fat and
liver, PAR2 only activated AMPK in b-arrestin-2
-/- mice. b-arrestin-2 could be co-immunoprecipitated with AMPK and
CAMKKb under baseline conditions from both cultured fibroblasts and primary fat, and its association with both
proteins was increased by PAR2 activation. Addition of recombinant b-arrestin-2 to in vitro kinase assays directly
inhibited phosphorylation of AMPK by CAMKKb on Thr172.
Conclusions: Studies have shown that decreased AMPK activity is associated with obesity and Type II Diabetes,
while AMPK activity is increased with metabolically favorable conditions and cholesterol lowering drugs. These
results suggest a role for b-arrestin in the inhibition of AMPK signaling, raising the possibility that b-arrestin-
dependent PAR2 signaling may act as a molecular switch turning a positive signal to AMPK into an inhibitory one.
Background
b-arrestins were first identified for their role in mediat-
ing G-protein-coupled receptor (GPCR) desensitization
and internalization, and were later discovered to serve
as signaling scaffolds mediating G-protein-independent
signaling. In our previous studies we have shown that
Proteinase-activated-receptor-2 (PAR2) can signal
through two different pathways, one involving Gaqc o u -
pling and mobilization of intracellular Ca
2+ and another
involving recruitment of various signaling proteins into
a scaffolding complex with b-arrestins [1-4]. As PAR2 is
reported to have both protective and pathogenic effects
in a number of diseases, the dominance of one pathway
over the other may direct the ultimate physiological
response [5,6]. Upon activation of PAR2 and a number
of other receptors, b-arrestins can associate with and
differentially regulate the activity of various signaling
proteins. For example, association with b-arrestins
increases the activity cofilin and ERK1/2, while inhibit-
ing the activity of PI3K [1-4,7]. Furthermore, studies on
other receptors suggest that b-arrestins can both posi-
tively and negatively regulate additional enzymes includ-
ing RhoA, phosphatase PP2A and NF-B [8,9].
PAR2 is one of a family of four GPCRs activated by
proteolytic cleavage of their N-termini, which exposes a
tethered ligand that then auto-activates the receptors.
Synthetic peptides corresponding to the tethered ligand
for PAR-1, 2 or 4 will specifically activate them in the
a b s e n c eo fp r o t e i n a s e[ 1 0 , 1 1 ] .M e m b e r so ft h i sG P C R
family share a common mechanism of activation, but
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pathways. For example, while PAR1 and PAR2 can cou-
ple to Gaq, PAR2 exhibits b-arrestin-dependent desensi-
tization and internalization, while PAR1 uses b-arrestins
only for desensitization. Downstream of PAR2, b-arrest-
ins scaffold and activate ERK1/2, while inhibiting PI3K.
In contrast, b-arrestins increase PAR1-stimulated PI3K
activity and inhibit ERK1/2 activation [1,12,13]. Previous
studies suggested that Gaq-coupled receptors, including
PAR1, promote AMPK activity through a Gaq/
CAMKKb-dependent mechanism, making AMPK a logical
metabolic target of PAR2 [14]; however, the role of
b-arrestins in AMPK signaling have never been investi-
gated. A major goal of this study was to examine the
p o s s i b l er o l eo fb-arrestins in the regulation of AMPK
downstream of PAR2.
AMPK is a heterotrimeric serine/threonine kinase
activated in response to decreased AMP/ATP ratios
[15-17], by classic signaling pathways that increase
CAMKK or LKB-1 activity, and by drugs such as statins,
metformin and thiazolidinediones [18-20]. While AMP
directly activates AMPK by inducing a conformational
change and by rendering it less susceptible to depho-
sphorylation by protein phosphatases 2A and C [21,22],
AMPK is further activated by phosphorylation on its a
s u b u n i ta tT h r1 7 2b yL K B - 1o rC a
2+/calmodulin
kinase-kinase b (CAMKK b) [19,23,24]. Activation of
AMPK is associated with a number of beneficial meta-
bolic effects, including phosphorylation and inhibition of
the enzyme acetyl coenzyme A carboxylase 1 (ACC1)
which is involved in fat synthesis. AMPK activity is
tightly regulated within the cell and there are a number
of pathological conditions associated with decreased
AMPK activity. Most research has focused on the
mechanisms by which it is activated downstream of dif-
ferent receptors; however, the possibility that receptors
can send negative signals to AMPK has not been as well
studied. Given the ability of PAR2 to promote two sepa-
rate signaling pathways leading to events that might be
considered protective and pathogenic from a metabolic
standpoint, we investigated whether it is capable of reg-
ulating AMPK and asked whether both Ca
2+-dependent
and b-arrestin-dependent signaling pathways were
involved.
Results
PAR2 promotes CAMKKb-dependent AMPK activity in
fibroblasts
To first determine whether PAR2 promotes AMPK acti-
vation, we treated NIH3T3 cells, with the PAR2 activat-
ing peptide 2-furoyl-LIGRL-O (2fAP) for 0-120 minutes
and assessed AMPK phosphorylation by performing
western blots with antibodies specific for Thr172 phos-
phorylated-AMPK and total AMPK (Figure 1A, C-D). A
negative control peptide comprising the reverse
sequence (2-furoyl-LRGIL-O) was used to show the
response was specific to 2fAP. Although serine protei-
nases are the physiological activators of PAR2,s y n t h e t i c
peptide agonists corresponding to the tethered ligand
are typically used to specifically activate the receptor, in
an experimental setting, to minimize confusion from
extraneous effects of proteinase treatment [11]. NIH3T3
cells were chosen for these initial studies because we
have previously demonstrated that they favor Gaqo v e r
b-arrestin-dependent signaling pathways [2]. PAR2 pro-
moted a 1.8-fold increase in AMPK phosphorylation,
peaking at 5 minutes and remaining slightly elevated for
2 hours (Figure 1A). We simultaneously examined phos-
phorylation of a known substrate of AMPK, using an
antibody specific for Ser79-phosphorylated ACC (Figure
1B, E-F), observing a similar increase in ACC phosphor-
ylation with 2fAP treatment (Figure 1A-F). Reverse 2fAP
did not increase AMPK phosphorylation, pointing to the
specificity of the response (Figure 1C). To further con-
firm that the increase in AMPK phosphorylation
reflected an increase in its activity, we immunoprecipi-
tated AMPKa from cells after stimulation with 2fAP for
0-120 minutes and assayed phosphorylation of the
AMPK substrate peptide (SAMS peptide); here we
observed a 2-3-fold increase in AMPK activity that
peaked at 5-15 minutes (Figure 1G, H). We conclude
that PAR2 promotes phosphorylation and activation of
AMPK, and its downstream substrate, ACC in NIH3T3
fibroblasts.
PAR2 is a Gaq coupled receptor, which leads to mobili-
zation of intracellular Ca
2+.S i n c eC A M K K b is a Ca
2+-
regulated kinase that can be activated by PAR2 [25], and
other Gaq-coupled receptors activate AMPK via
CAMKKb, we examined its role in PAR2 stimulated
AMPK activity using the inhibitor STO-609. At the
concentration used, (10 μg/ml), STO-609 is considered
specific for CAMKKb and although it exhibits non-speci-
ficity at higher concentrations, it does not affect the
activity of LKB1, the other primary AMPKK [26]. In the
presence of STO-609, PAR2-induded AMPK phosphory-
lation was blocked. In fact, although STO-609 treatment
did not significantly decrease baseline pAMPK levels, we
observed a mild decrease in AMPK phosphorylation
below baseline levels upon PAR2 stimulation (Figure 2A-
C). These data suggest that PAR2 is capable of inhibiting
as well as promoting AMPK phosphorylation, an obser-
vation that is consistent with previous studies in which
we demonstrated that a number of Gaq/Ca
2+-dependent
signaling pathways are opposed by b-arrestins and vice
v e r s a[ 2 , 4 ] .W ec o n c l u d et h a tP A R 2 stimulated AMPK
activation requires the activity of CAMKKb and may
b eo p p o s e db yas e p a r a t eP A R 2 stimulated pathway.
We address whether this inhibitory pathway is
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Page 2 of 15Figure 1 PAR2 promotes AMPK activation in NIH3T3 cells. A-C. Representative westerns of phospho- and total AMPK (A, C)o rp h o s p h o -a n d
total Acetyl CoA Carboxylase (pACC) (B) in lysates from cells treated with or without 100nM 2fAP (to activate PAR2) for 0-120 minutes (A, B) or
treated with a negative control peptide containing the reverse tethered ligand sequence, 2-Furoyl-LRGIL-O (RAP) (C). Integrated band intensity was
determined for phospho- and total AMPK and Acc using LICOR Odyssey software and phosphorylated protein was normalized to total protein
levels for each sample. Graphs of fold changes over baseline (D, F) or raw values for normalized phospho-protein (E, G) are shown for AMPK (D, E)
or Acc (F, G). Baseline is defined as pAMPK levels observed in the absence of 2fAP treatment. AU refers to integrated intensity values as arbitrary
units. Statistically significant differences between treated and baseline are indicated by ** (p < .005) and * (p < .05). G-H. To determine AMPK
activity, AMPK was immunoprecipitated from cells after treatment with 2fAP for 0-120 minutes, incubated with the substrate SAMS peptide in the
presence of
32P-ATP and reactions spotted onto phospho-cellulose filters. Radiolabel incorporation was determined by scintillation counting of
filters and nmoles of phosphate incorporated per mg of AMPK was calculated (H). Fold changes in AMPK activity were determined as the ratio of
radiolabel incorporated in treated over untreated controls (I). (*statistically significant increase in activity, p < .05, n = 8).
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Page 3 of 15mediated by b-arrestins, similar to what has been
observed for other proteins [2,4] in the next section.
The other kinase capable of activating AMPK is LKB-1,
a tumor suppressor, which is activated by STRAD and
STE-20-related kinases and which potentiates the effect
of AMP on AMPK activity [27,28]. Transfection of
siRNA to LKB-1 reduced LKB-1 protein by 70%, and
resulted in a 50% decrease in PAR2-stimulated AMPK
Figure 2 PAR2-stimulated AMPK activation requires input from CAMKKb and LKB-1. A. Representative western blot of pAMPK and tAMPK
in lysates from NIH3T3 cells, pretreated with vehicle (control, left panel), with 10 μg/ml STO-609 (middle panel), or with 300nM BAPTA-AM (right
panel), followed by treatment with 2fAP for 0-120 minutes. Bar graphs showing raw normalized pAMPK levels (B) or fold changes over baseline
in normalized pAMPK (C) (n = 4). Baseline is defined as pAMPK observed in the absence of 2fAP in vehicle-treated cells. D-G. Cells were
transfected with control (cnt) or LKB-1 siRNA and AMPK phosphorylation was determined as described above. Representative westerns showing
anti-LKB-1 with and without siRNA knockdown (D) and phospho and total AMPK levels with and without LKB knockdown (E) are shown. Bar
graphs show normalized pAMPK levels (F) or fold changes in pAMPK relative to baseline (G) after cnt or LKB-1 siRNA (n = 3). Baseline is defined
as pAMPK observed in cntsiRNA transfected, untreated cells.
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Page 4 of 15phosphorylation (Figure 2D-G). We next measured AMP
and ATP levels in cells treated with or without 2fAP for
0-120 minutes by liquid chromatography-tandem mass
spectrometry (LC-MS/MS). PAR2 increased AMP/ATP
ratios at 120 minutes and to a lesser extent at 5 minutes
(Figure 3). We conclude that LKB-1 also contributes to
AMPK phosphorylation downstream of PAR2,, which
may involve increased AMP/ATP ratios observed in
response to PAR2 activation. Because CAMKKb signaling
downstream PAR2 is better understood, and the effect of
CAMKKb inhibition on PAR2 stimulated AMPK phos-
phorylation was more pronounced than that of LKB1, the
remainder of these studies will focus on the CAMKKb
arm of this signaling pathway.
b-arrestin-2 inhibits PAR2 stimulated AMPK activation
In light of studies suggesting that PAR2-induced, Ca
2
+-dependent activation of other enzymes is inhibited by
b-arrestins [2-4], we hypothesized that b-arrestins might
be capable of inhibiting the PAR2 stimulated increase in
AMPK phosphorylation. We examined AMPK phos-
phorylation in mouse embryonic fibroblasts from wild
type mice (wtMEF), b-arrestin double knockout mice
(MEFbarrDKO), or from MEFbarrDKO transfected with
either b-arrestin-1 (DKO+barr1) or b-arrestin-2 (DKO
+barr2). These transfected MEFs have been previously
characterized and found to express levels of either b-
arrestin-1 or 2 similar to those expressed in the wild
type cells, and avoid the possible complications of com-
pensatory mechanisms that may be present in either b-
arrestin-1 or b-arrestin-2 knockout mice [29]. In
wtMEF, no significant increase in AMPK phosphoryla-
tion was observed upon PAR2 activation, consistent with
the higher levels of b-arrestins present in MEFs com-
pared with NIH3T3 cells [2]. However, in MEF-
barrDKO, and in MEFDKO+barr1, PAR2 promoted a 2-
2.5-fold increase in AMPK phosphorylation. In contrast,
in MEFDKO+barr2, PAR2 stimulated AMPK phosphory-
lation was inhibited (Figure 4A, B). Furthermore, when
flag-b-arrestin-2 was over-expressed in NIH3T3 cells,
PAR2 stimulated AMPK phosphorylation was abolished
(Figure 4C, D). In NIH3T3 cells over-expressing b-
arrestin-2, we observe a small (<10%) increase in base-
line pAMPK (i.e. pAMPK levels in the absence of PAR2
agonists). We do not yet know the significance of this
alteration in basal AMPK phosphorylation but may
reflect a PAR-2-independent effect of b-arrestin on
AMPK phosphorylation. b-arrestins are involved in ter-
minating the signals of a number of receptors known to
activate AMPK. PAR2 is relatively unusual in that it pro-
motes a number of b-arrestin-dependent signaling
events, while its G-protein signal is being dampened.
We conclude that b-arrestins can inhibit PAR2 stimu-
lated AMPK phosphorylation.
PAR2 promotes b-arrestin-dependent inhibition of AMPK
in primary fat
To confirm the inhibitory role of b-arrestin-2 on AMPK
phosphorylation in primary cells, we investigated PAR2-
stimulated AMPK phosphorylation in adipose tissue
from wild type and either b-arrestin-1
-/- or b-arrestin-
2
-/- mice. AMPK activity in adipose plays a key role in
modulating the metabolic state of the animal [30,31]
and we observe high levels of b- a r r e s t i ne x p r e s s i o ni n
primary fat as well as differentiated 3T3L1 adipocytes
(Wang and DeFea, unpublished observations). Isolated
epididymal fat was incubated with or without 2fAP for 5
and 120 minutes, then homogenized and analyzed by
SDS-PAGE followed by western blotting for phospho-
AMPK. In wt and b-arr1
-/- fat, no significant increase in
AMPK activity was observed in response to PAR2 activa-
tion. However, in b-arr2
-/- fat, PAR2 promoted a 5-fold
increase in AMPK phosphorylation (Figure 5B-E), and a
1.5-2.5-fold increase in AMPK activity (Figure 5F, G).
Similar results were observed in liver from wt, b-arr-1
-/-
and b-arr2
-/- animals (not shown). Pretreatment with
STO-609 abolished PAR2-stimulated AMPK phosphory-
lation in b-arr2
-/- fat (Figure 5H, I), suggesting that
AMPK phosphorylation by CAMKKb is inhibited by b-
arrestin-2. Consistent with these observations, PAR2
-stimulated phosphorylation of the AMPK substrate,
ACC, was only observed in b-arr2
-/- mice (Figure 6).
We conclude that PAR2 can promote CAMKKb-depen-
dent AMPK activation in primary fat, but under normal
conditions this activity is suppressed by an inhibitory
PAR2 pathway through b-arrestin-2.
AMPK and CAMKKb associate with b-arrestin-2
Our studies on PI3K suggest that b-arrestins can form
inhibitory scaffolds leading to decreased kinase activity.
To examine whether b-arrestins similarly associate with
AMPK and CAMKKb, we performed co-immunopreci-
pitations in NIH3T3 cells transfected with flag-tagged b-
arrestin-1 or b-arrestin-2, treated with and without
2fAP. Both AMPK and CAMKKb could be co-precipi-
tated with b-arrestin-2 and to a lesser extent, b-arrestin-
1. Only b-arrestin-2 increased association with AMPK
and CAMKKb upon PAR2 activation (Figure 7A-C).
Furthermore, a greater amount of both proteins asso-
ciated with b-arrestin-2 relative to its expression level,
than with b-arrestin-1 (Figure 7B, C). Confirming the
specificity of this interaction, CAMKKb and AMPK
were not immunoprecipitated with anti-flag in mock
transfected cells (see Figure 7A, left most lanes). We
confirmed association of endogenous b-arrestins with
AMPK and CAMKKb i nf a te x p l a n t s ,w h e r ew ei m m u -
noprecipitated AMPKa1 and probed western blots with
b-arrestin-1/2 or CAMKKb antibodies. AMPK could be
co-immunoprecipitated with CAMKKb and b-arrestin-2
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Page 5 of 15Figure 3 PAR2 increases cellular AMP/ATP levels. NIH3T3 cells were treated with 2fAP for 0-120 minutes or with DNP as a positive control.
Nucleotides were extracted and analyzed by LC-ESI-MS/MS. A-D. Representative selected-ion chromatograms of ATP and AMP, shown above the
peaks are the integrated peak area (AA) and retention time. E. Fold changes in AMP/ATP were calculated for each treatment group compared to
untreated controls. The results were from three independent measurements.
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Page 6 of 15( F i g u r e7 D ) .T h e r e f o r e ,w ec o n c l u d et h a tb-arrestin-2
might form an inhibitory complex with AMPK and its
upstream kinase, CAMKKb.
b-arrestin-2 directly inhibits CAMKKb activity in vitro
To examine whether b-arrestin-2 can directly inhibit
CAMKKb activity, thus preventing phosphorylation of
AMPK, we incubated recombinant GST-tagged b-
arrestin-2 or GST alone (as a negative control) with
recombinant CAMKKb in the presence of
32P-ATP and
the substrate myelin basic protein (MBP). CAMKKb
activity was determined by quantifying incorporation of
32P into MBP. Reactions were performed with 50ng
CAMKKb and carried out for 15 minutes, which
resulted in maximal MBP phosphorylation (Figure 8A,
B). Phosphorylation of MBP by CAMKKb was inhibited
in a dose-dependent fashion upon addition of b-
arrestin-2-GST but not GST alone (Figure 8C, D), sug-
gesting an overall inhibitory effect of b-arrestin-2 on
CAMKKb activity. We then specifically examined phos-
p h o r y l a t i o no fA M P Ko nT h r 1 7 2 .C A M K K b was incu-
bated with recombinant heterotrimeric AMPK in the
Figure 4 Expression of b-arrestin-2 inhibits PAR2 stimulated AMPK activation. A, B. Mouse embryonic fibroblasts from wt embryos (wtMEF),
b-arrestin double knockout embryos (MEF barrDKO), or MEFbarrDKO stably expressing barrestin-1 (DKO+barr1) or b-arrestin-2 (DKO+barr2) were
treated with 2fAP for 0, 5 or30 minutes and analyzed as described in Figure 1. A. Representative western blots of pAMPK and tAMPK in each cell
line are shown in the upper two panels. The lower panel shows b-arrestin expression in each cell line. B. Bar graphs depicting normalized
phospho-AMPK levels (upper) and fold changes over baseline in pAMPK/tAMPK (lower) in each cell line. Baseline is defined as pAMK observed in
the absence of 2fAP for each cell line. C. Cells were transfected with an empty vector or flag-b-arrestin-2, treated with 2fAP for 0, 5 or 30
minutes and analyzed as described above. Upper panels: anti-pAMPK and tAMPK; lower panels: anti-b-arrestin was used to confirm expression of
transgene. D. Bar graph showing fold changes compared with baseline in pAMPK in cells transfected with vector or Flagbarr2. Baseline in these
experiments is defined as pAMPK in untreated, vector transfected cells.
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Page 7 of 15Figure 5 PAR2-induced AMPK activation in primary fat is enhanced in the absence of b-arrestin-2.A .b-arrestin expression levels in
extracts from wt mice, b-arrestin-1
-/- mice and b-arrestin-2
-/- mice were examined using antibody that recognizes both b-arrestin-1 and 2
(preferentially reacts with b-arrestin-1). Epidydimal fat pads from male wild type (wt) and b-arrestin-2-/- (B) or wt and b-arrestin-1-/- (C) mice
were harvested and treated with or without 2fAP for 0-120 minutes, and phosphor-AMPK determined as described in Figure 1. A total of 15
mice from each experimental group were analyzed. Representative westerns are shown in B and C. Levels of pAMPK normalized to tAMPK were
determined as described in Figure 1 and mean μ SEM pAMPK/tAMPK across all samples is presented as a bar graph of for all mice (D). The same
data is also presented as dot plots showing fold changes over baseline in pAMPK levels for individual mice (E, note 0 minutes = baseline and is
not included in the plot) and showing normalized phospho-AMPK levels of individual mice (F) *Statistically significant differences in mean
pAMPK compared with wt mice (p < .005, n = 15). Statistically significant differences between 2fAP-treated and baseline pAMPK were only
observed in b-arrestin-2-/- mice (p = .001, n = 15). This experiment was repeated in liver samples, included as Supplemental Figure 1. G, H.
AMPK activity was determined as described in Figure 1 for AMPK immunoprecipitated from wt and b-arrestin-2
-/- fat and is depicted as fold
change over baseline (G) and pmoles of ATP incorporated per mg of immunoprecipitated AMPK (H). I. Fat from b-arrestin-2
-/- mice was
prepared as described in A, but was pretreated with STO-609 prior to activation of PAR2 with 2fAP for 0, 5 and 120 minutes. Shown are
representative westerns of phospho-AMPK and total AMPK (upper panel) and a bar graph of normalized pAMPK levels in the presence and
absence of STO-609 at each time point(lower panel).
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Page 8 of 15presence and absence of 500pM GST-b-arrestin-2 (the
concentration at which MBP phosphorylation was inhib-
ited by 80% in Figure 8D) or with GST alone, and
phosphorylation determined by western blot using anti-
phospho-AMPK and anti- total AMPK. CAMKKb-
stimulated AMPK phosphorylation was abolished by
addition of recombinant GST-b-arrestin-2, but not GST
(Figure 8E, F).
Discussion
Here we describe a novel role for b-arrestin-2 in the
regulation of AMPK, downstream of PAR2.W ed e m o n -
strate that PAR2 can activate AMPK in the presence of
low b-arrestin-2 levels, and inhibit it in cells with high
levels of b-arrestin-2. While previous studies have inves-
tigated the mechanism of AMPK activation by another
proteinase-activated receptor, PAR1, those studies did
not deal with b-arrestins. Furthermore, the role of
b-arrestins in signaling by the two receptors is quite
different. PAR2 activation of AMPK involves the Ca
2+
sensitive enzyme, CAMKKb, while the inhibitory path-
way involves b-arrestin-dependent suppression of this
same activity (depicted in Figure 9). As was observed for
PAR1, LKB-1 may also play a role in PAR2-stimulated
AMPK activation, but the sensitivity of this enzyme to
b-arrestin-dependent regulation remains to be investi-
gated. Research by ours and other groups over the last
few years has revealed that b-arrestins can direct signals
that oppose, facilitate, or act independently of a number
of G-protein-directed signals [32]. With respect to
PAR2,w eh a v es h o w nt h a tC a
2+ mobilization, down-
stream of Gaq activation, promotes nuclear MAPK
activity, PI3K activity and LIMK activation, while b-
arrestins promote inhibition of PI3K and LIMK and
membrane sequestration of MAPK activity [1-4,33]. The
predominance of one pathway over the other depends
largely on the relative amounts of Gaqa n db-arrestins,
which appear to vary in a cell-type specific fashion [2].
Thus, the same extracellular signal can elicit distinct
responses through the same receptor depending on the
cellular context.
These findings also provide novel insight into the scaf-
folding functions of b-arrestin-2. To date, numerous
binding partners have been identified for b-arrestins
encompassing a diverse array of proteins including
MAPKs, phosphatidylinositol kinases, actin assembly
proteins, transcription factors, RhoGTPases, and ubiqui-
tin ligases [8,32]. Interestingly, individual receptors pro-
mote recruitment of only a select group of these
potential binding partners to b-arrestins. Part of this
diversity can be explained by discrete domains within b-
arrestins that serve as docking sites for different binding
partners. Here we identify two new targets of b-arrestin-
2-dependent scaffolding: CAMKKb and AMPK which
co-immunoprecipitate in cultured cells and in vivo.
Although it is not yet clear whether either or both
CAMKKb and AMPK directly contact b-arrestin-2, it is
likely that CAMKKb directly interacts with b-arrestin-2,
since addition of b-arrestin-2 blocked phosphorylation
o fb o t han o n - s p e c i f i cs u b s t r a t e( M B P )a n das p e c i f i c
one (AMPK1a). Furthermore, it is formally possible that
AMPKa may directly bind b-arrestin, because it con-
tains a stretch of amino acids within its N-terminus that
bears with similarity to a recently identified conserved
region in Jnk3 and CAMKg, both of which constitutively
bind b-arrestin-2 [34,35]. It will be interesting to deter-
mine whether AMPKa directly binds b-arrestin-2,
whether it binds to the same region as Jnk3 and
CAMKg and whether these proteins compete for inter-
action with b-arrestin-2. While we demonstrated that
interaction of b-arrestin-2 with AMPK and CAMKKb in
cells was enhanced by activation of PAR2, co-immuno-
precipitation of all three proteins was observed in
mouse fat in the absence of treatment, suggesting that
this scaffolding complex may exist constitutively in vivo.
Our data suggest that association of b-arrestin-2 with
these proteins is strengthened by PAR2 activation. The
conformational rearrangement that b-arrestin-2 under-
goes upon receptor binding may alter the nature of the
contacts between these proteins resulting in the
observed inhibitory effect. Additional factors may also
contribute to the inhibitory effect of b-arrestin-2 on
Figure 6 PAR2 increases ACC phosphorylation in primary fat
from b-arrestin-2
-/- mice. Fat from wt and b-arrestin-2
-/- mice,
prepared as described in Figure 4 was analyzed by western blot for
pACC (upper panel) or actin (lower panel). Dot-plots showing
normalized fold changes relative to baseline in pACC for individual
mice are shown below (Baseline (untreated) is equal to 1, and is not
shown in the graph). *Statistically significant changes in mean pACC
compared with wt mice (p < .001, n = 11).
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Page 9 of 15Figure 7 Co-immunoprecipitation of b-arrestin-2, CAMKKb a n dA M P Ki nN I H 3 T 3c e l l sa n dp r i m a r yf a tt i s s u e . A-C. NIH3T3 cells,
transfected with empty vector (as a negative control for Co-IPs) or flag-tagged b-arrestin-1 or 2, were treated with 2fAP for 0-120 minutes, lysed
and b-arrestins immunoprecipitated with anti-flag, followed by western blotting with anti-AMPK, CAMKKb and Flag. Expression of b-arrestin-1
was higher than that of b-arrestin-2 so AMPK and CAMKKb protein levels in each immunoprecipitation were normalized to normalized to b-
arrestin-1 or 2 levels. Bar graphs depicting quantification of immunoprecipitated AMPK (B) and CAMKKb (C) are shown (n = 4). D. Epidydimal fat
from wt mice was harvested and lysates were immunoprecipitated with AMPK or IgG followed by western blotting with antibody to AMPK
(upper), CAMKKb (middle panel) and b-arrestin-1/2 (lower panel). IgG heavy chain can be seen at 50kD in the b-arrestin panel. The band above
IgG corresponds to b-arrestin-1 and the band below corresponds to b-arrestin-1.
Wang et al. BMC Biochemistry 2010, 11:36
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Page 10 of 15Figure 8 b-arrestin-2 inhibits CAMKKb activity and AMPK phosphorylation in vitro. A, B. Conditions for optimal CAMKKb concentrations
and reaction times were determined. A. Increasing concentrations (0-100ng) of recombinant CAMKKb were incubated with 1 μg of the substrate
MBP in the presence of 32-P-ATP for 15 minutes. Reactions were analyzed by SDS-PAGE and radiolabel incorporation into excised MBP bands
was determined. The upper panel is a representative autorad and the lower panel is the same gel stained with Coomassie Blue to show protein
loading. B. Recombinant CAMKKb (50ng) was incubated with 1 μg MBP and 32-P-ATP for 0-40 minutes and analyzed as described above. C-D.
CAMKKb kinase reactions using MBP as a substrate were repeated (50ng CAMKKb, 15 minute reactions) in the presence of increasing
concentrations of either recombinant GST or b-arrestin-GST and
32P-ATP. C. Representative autorad (Upper) of kinase reaction and corresponding
coomassie stained gels (lower) are shown in the upper two panels. Levels of GST and b-arrestin-2-GST are shown in the inset at the bottom. D.
Mean μ SEM CAMKKb activity in the presence of GST and GST-b-arrestin-2 is shown (n = 4). E. Recombinant AMPK was incubated with or
without CAMKKb alone, and with CAMKKb in the presence of 500pM GST or 500pM GST-b-arrestin-2. Samples were analyzed by SDS-PAGE
followed by western blotting with anti-phospho-AMPK (upper) and anti-total AMPK (lower) F. Graphs depicting normalized pAMPK levels (left
panel) and fold increase in pAMPK relative to baseline (right panel). Baseline is defined as AMPK phosphorylation observed in the absence of
CAMKKb,n=3 .
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Page 11 of 15AMPK in vivo. For example, b-arrestin-2 has been
shown to bind and inhibit calmodulin which could con-
tribute to the inhibition of CAMKKb activity in cells. b-
arrestin-2 has also been shown to scaffold PP2A to one
o fi t ss u b s t r a t e sa n ds c a f f o l d i n go fP P 2 At oA M P K
might further inhibit its phosphorylation [36]. Finally, b-
arrestins also play a role in the desensitization of
numerous receptors, ones that both activate and inacti-
vate AMPK, such as adiponectin receptor. Thus, the
absence of b-arrestin-2 may have the opposite effect on
receptors that regulate AMPK independent of
CAMKKb.
These findings are likely to have implications in terms
of metabolic regulation, although this possibility was not
specifically addressed here. There is increasing evidence
that obesity can be viewed as an inflammatory disorder,
associated with increased circulating inflammatory cyto-
kines and macrophage infiltration into fat, which in turn
exacerbates defects associated with Type 2 Diabetes.
PAR2 has been implicated in numerous inflammatory
pathways and there is some evidence that b-arrestin
levels can be altered under different physiological condi-
tions [37,38] and in a mouse model of insulin resistance
(db/db mice) [39]. b-arrestins have also been reported
to contribute to insulin resistance by mediating a
TNFa-induced inflammatory pathway [40]. There are a
number of potential physiologically relevant agonists of
PAR2 in the tissues examined here. Adipocytes secrete a
trypsin-like enzyme called adipsin [41] that might acti-
vate PAR2 and Diabetes is associated with increased
levels of mast-cell infiltration into the fat, and increased
release of tryptase, another physiological activator of
PAR2 [42]. Factor VIIa, another known PAR2 agonist, is
also reported to be elevated in Diabetes and decreased
with strenuous exercise [43,44]. Future studies should
address whether PAR2 activation has different effects on
parameters associated with obesity in wild type versus
b-arrestin-2 knockout mice, and address the effects of
PAR2 on fat synthesis in cells.
Conclusions
PAR2 can both activate and inhibit AMPK through dis-
tinct signaling pathways. First, via activation of
CAMKKb and to a lesser extent LKB-1, PAR2 can pro-
mote phosphorylation of AMPK and subsequent phos-
phorylation of its downstream substrate ACC. Second,
via coupling to b-arrestin-2, PAR2 can inhibit AMPK
phosphorylation. This inhibitory effect is mediated by
association of b-arrestin-2 with AMPK and CAMKKb,
which results in direct inhibition of CAMKKb activity.
Methods
Materials
All chemicals were from Sigma or Fisher Scientific
except as otherwise indicated. PAR2 agonist, 2-Furoyl-
LIGRL-O-NH2 (2f-AP), was synthesized by Genemed
Inc. STO-609, a specific inhibitor for CAMKKb was
from Tocris.
Animals
All procedures in the animal experiments were in accor-
dance with the guidelines on the use and care of labora-
tory animals set by NIH and approved by the IACUC,
University of California, Riverside. b-arrestin1
-/- and b-
arrestin2
-/- in a C57BL/6 background were kindly pro-
vided by Dr. Robert Lefkowitz (DUMC, Durham, NC)
and wild type C57BL/6 mice were from Jackson Labs.
All strains of mice were bred at UC Riverside, were
Figure 9 Model for PAR2 regulation of AMPK activity.P A R 2 can
activate G-protein pathways leading to Ca2+ mobilization and
CAMKKb activation, which then lead to phosphorylation and
activation of AMPK. LKB1 also contributes to PAR2-stimulated AMPK
activation, either through activation of the enzyme itself or by
inducing a conformational change in AMPK that renders it more
sensitive to phosphorylation by LKB1. At later time points, we
predict that PAR2 may inhibit the activity of a phosphatase or
protect AMPK from dephosphorylation, thus leading to the
observed prolonged activation. Simultaneously, PAR2 can recruit b-
arrestin-2 which binds both AMPK and CAMKKb and prevents
phosphorylation of AMPK. The resulting shift in the balance of
phosphorylation and dephosphorylation of AMPK can lead to an
observed decrease in overall AMPK phosphorylation in the presence
of b-arrestin-2.
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Page 12 of 15provided with standard rodent chow and water, and
were housed under normal laboratory conditions (12 hr
light/12 hr dark cycle). Age matched male mice (12~16-
week-old) were used for this study.
Cell Culture and Transient Transfections
Mouse embryonic fibroblasts (MEF) from wild type and
b-arrestin knockout mice (from Dr. Robert Lefkowitz,
D U M C )a n dN I H 3 T 3c e l l sw e r eg r o w ni nD u l b e c c o ’s
modified Eagle’s medium (DMEM, Mediatech) supple-
mented with 10% cosmic calf serum (Hyclone Labora-
tories) and maintained at 37°C with 5% CO2.C e l l s
(approximately 70% confluent) were transiently trans-
fected with 10 μg of FLAG-tagged b-arrestin-1 or -2
(from Dr. Robert Lefkowitz, DUMC) using Ca
2+ phos-
phate precipitation and harvested for experiments 36-48
h after transfection.
Preparation of tissue and cell extracts
Visceral epidydimal fat pads and livers were harvested,
washed in ice-cold saline and dissected rapidly into 3-5
mg pieces, followed by pre-incubation for 20 minutes in
Krebs Ringer HEPES Buffer (pH 7.4) at 95%O2/5%CO2
at 37°C [45,46]. Samples were maintained at 95%O2/5%
CO2 at 37°C for the duration of the experiments. Sam-
ples from individual mice were each assayed as separate
experimental groups so that a given PAR2 stimulated
AMPK response could be attributed to a single mouse.
For cell culture studies, cells were used at 80% conflu-
ence and complete media was exchanged for serum free
media 2 hours prior to the experiments. Tissues or cells
were treated with or without 100nM of 2fAP- at 37°C
and then homogenized in ice-cold lysis buffer containing
TBS pH 7.4 supplemented with 1 mM EGTA, with pro-
teinase and phosphatase inhibitors and either 1%Triton
X-100 and 0.1% SDS (for total lysates analysis) or 1%
NP-40 (for co-immunoprecipitations), followed by cen-
trifugation for 10 min at 14,000 rpm at 4°C.
Adenine Nucleotide Measurement by LC-MS/MS
NIH3T3 cells (grows at 80% confluence) were incubated
with 100 nM of 2f-AP for 0-2 hrs, washed in cold PBS
and 5% (wt/vol) of perchloric acid was added to the
cells. Acid-insoluble material was removed by centrifu-
gation, and perchloric acid was extracted from the
supernatant by three washes with 10% excess (by
volume) of a 1:1 mixture of tri-n-octylamine and 1,1,2-
trichlorotrifluoroethane. The nucleotide mixture was
subjected to online LC-ESI-MS/MS (liquid chromatogra-
phy-electrospray ionization-tandem mass spectrometry)
analysis using an Agilent 1100 capillary HPLC pump
(Agilent Technologies) interfaced with an LCQ Deca XP
ion-trap mass spectrometer (Thermo Fisher Scientific).
The mass spectrometer was set up for monitoring the
fragmentation of the [M-H]
- ions of AMP (m/z 346)
and ATP (m/z 506). A 0.5 × 250 mm Zorbax SB-C18
column (5 μm in particle size, Agilent Technologies)
was used, and the flow rate was 8.0 μL/min. A 5-min
gradient of 0-20% methanol in 400 mM 1,1,1,3,3,3-hexa-
fluoro-2-propanol (HFIP, pH adjusted to 7.0 by addition
of triethylamine), followed by a 25-min gradient of 20-
50% methanol in 400 mM HFIP was employed for the
separation. The ratio of AMP over ATP was calculated
by comparing the integrated areas of AMP to ATP from
selected ion chromatograms (SICs) with the considera-
tion of the differences in ionization and fragmentation
efficiencies of the two nucleotides.
Protein analysis and immunoblotting
Lysates from cells and liver or fat tissue (10 μgp r o t e i n )
were subjected to 8% SDS-PAGE gel and transfer to
PVDFfl (Millipore) membranes, followed by Western
blotting with the following antibodies: Rabbit polyclonal
anti-phosphor-AMPK-Thr
172 or anti-phosphor-ACC-
Ser
79 (both from Cell Signaling, 1:1000); mouse mono-
clonal anti-AMPKa1+2 (ProSci, 1:1000), rabbit anti-Flag
(1:1000), rabbit anti-b-arrestin (A1CT, from Dr. Robert
Lefkowitz, DUMC, 1:500) or rabbit anti-CAMKKb
(Upstate Biotech). Blots were imaged with Alexa
680-con-
j u g a t e dr a b b i t( I n v i t r o g e n )a n dI R
800-conjugated mouse
(Rockland) secondary antibodies (1:40,000 each) using
the LICOR Odyssey imaging system, and LICOR soft-
ware was used to calculate integrated intensities of
bands; phospho-AMPK and ACC levels were normalized
total AMPK and actin respectively. Fold increases in
phosphorylation were determined by dividing the band
density observed with treatment by that observed in the
absence of treatment. Images of Western blots were
assembled using Adobe Photoshop 6.0 and imported
into Adobe Illustrator. Some gels were spliced to elimi-
nate blank lanes or lanes containing samples unrelated
to the figure and splicing is indicated by a white space.
Co-immunoprecipitation
Cleared lysates (500 μg of protein) were incubated with
20 μl of mouse anti-FLAG agarose conjugated antibodies
pre-bound to protein A-agarose with mouse anti-
AMPKa1a n d2( 1μg/200 μg protein) coupled to Protein
G agarose for 2hrs at 4°C on a rotator. Immune com-
plexes were resolved by 10% SDS-PAGE and western
blotting performed as described.
In vitro AMPK Assays
AMPK was immunoprecipitated from cleared lysates
with anti-AMPKa1/2 (1 μg/200 μg protein) as described
above. Washed immune complexes were then used for
AMPK assays. AMPK activity was determined by the
incorporation of
32P-ATP (Perkin Elmer) into a synthetic
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peptide (Upstate Technologies), in the presence of 5 mM
MgCl2, 200 μM AMP and 200 μM[ g-
32P] ATP (0.05 μCi/
μl). Phosphorylated SAMS peptide was captured on
phospho-cellulose strips (Pierce) and counted in a Beck-
man Scintillation counter; levels of AMPK present in
each reaction was determined by western blotting of
AMPK immune complexes after removal of reaction mix-
ture, by comparing band density to that of a known
quantity of purified recombinant AMPKa. Either the fold
increase in activity was determined by dividing the nor-
malized cpm incorporated with 2fAP treatment by that
observed in the absence of stimulus or the moles ATP
incorporated into each reaction was determined and
expressed as nmoles ATP/mg enzyme/min.
In vitro CAMKKb Kinase Assays
GST alone and GST-tagged b-arrestin-2 (from Dr. Kerri
Mowen, The Scripps Research Institute) was purified as
described previously [3]. Recombinant active CAMKK2
(50ng, SignalChem) was incubated with the substrate
MBP (5 μg/reaction), 200 μM ATP (with 0.5 μCI [g-
32P]
ATP) and 5 mM MgCl2 i nt h ep r e s e n c eo fi n c r e a s i n g
concentrations of recombinant GST alone or GST-b-
arrestin-2 at 30°C for 15 min. The enzyme concentra-
tion chosen represented the IC50 value determine in
Figure 8A and the reaction time was chosen because at
this point MBP phosphorylation was maximal (Figure
8B). Reactions were stopped with addition of Laemmli
sample buffer and boiling; samples were then analyzed
by SDS-PAGE followed by autoradiography. MBP bands
were excised and phosphate incorporation was deter-
mined using a BECKMAN scintillation counter. For
non-radioactive experiments, recombinant active
CAMKKb (50ng) was incubated with 200nG AMPK
(Cell Signaling) in the presence of GST or purified b-
arrestin-2-GST in PBS, 1 mM ATP and 5 mM MgCl2 at
30°C for 30 minutes. Reactions were analyzed by SDS-
PAGE followed by western blotting with anti-phospho
and anti-total AMPK antibodies.
Data Analyses
All experiments were repeated a minimum of three
times and results are presented as mean μ S.E.M. Differ-
ences between multiple groups were examined by two-
way ANOVA and Tukey t-tests using graphing software
Microsoft Excel or GraphPad Prism, with P <0 . 0 5c o n -
sidered significant.
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